Literature DB >> 17207162

Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.

B Noël1.   

Abstract

BACKGROUND: Statins have been increasingly associated with drug-induced autoimmune reactions, including lupus erythematosus.
OBJECTIVE: To identify and determine the clinical and biological characteristics of statin-induced autoimmune reactions.
MATERIAL AND METHODS: The MEDLINE database (1966 to September 2005) was used to identify all reported cases of statin-induced autoimmune diseases. The keywords used were statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, adverse effects, autoimmune disease, lupus erythematosus, dermatomyositis and polymyositis.
RESULTS: Twenty-eight cases of statin-induced autoimmune diseases have been published so far. Systemic lupus erythematosus was reported in 10 cases, subacute cutaneous lupus erythematosus in three cases, dermatomyositis and polymyositis in 14 cases and lichen planus pemphigoides in one case. Autoimmune hepatitis was observed in two patients with systemic lupus erythematosus. The mean time of exposure before disease onset was 12.8+/-18 months; range 1 month-6 years. Systemic immunosuppressive therapy was required in the majority of cases. In many patients, antinuclear antibodies were still positive many months after clinical recovery. A lethal outcome has been recorded in two patients despite aggressive immunosuppressive therapy.
CONCLUSION: Long-term exposure to statins may be associated with drug-induced lupus erythematosus and other autoimmune disorders. Fatal cases have been reported despite early drug discontinuation and aggressive systemic immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17207162     DOI: 10.1111/j.1468-3083.2006.01838.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  30 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  Is it safe to use statins in patients with myasthenia gravis?

Authors:  Nils Erik Gilhus
Journal:  Nat Clin Pract Neurol       Date:  2008-12-09

3.  A case of psoriasis worsened by atorvastatin.

Authors:  Emanuele Cozzani; Manuela Scaparro; Aurora Parodi
Journal:  J Dermatol Case Rep       Date:  2009-12-30

4.  The beneficial effects of statin therapy may not apply to all forms of crescentic glomerulonephritis.

Authors:  Bahjat Al-Ani; Hamad Al Nuaimi; Caroline Savage
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

5.  62-year-old woman with fever, dyspnea, pleuritic chest pain, and weight loss.

Authors:  Brandon P Verdoorn; Furman S McDonald
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

Review 6.  The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review.

Authors:  Christos G Mihos; Rosa T Artola; Orlando Santana
Journal:  Rheumatol Int       Date:  2011-07-31       Impact factor: 2.631

7.  Simvastatin-induced dermatomyositis in a 50-year-old man.

Authors:  Inés Rania Zaraa; Imen Labbène; Dalila Mrabet; Hela Zribi; Inès Chelly; Mohamed Zitouna; Mourad Mokni; Slaheddine Sellami; Amel Ben Osman
Journal:  BMJ Case Rep       Date:  2011-03-29

Review 8.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

9.  Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

Authors:  Agustin Castiella; Eva Zapata; M Isabel Lucena; Raúl J Andrade
Journal:  World J Hepatol       Date:  2014-04-27

10.  Effect of statin use on the risk of rheumatoid arthritis: A systematic review and meta-analysis.

Authors:  Elena Myasoedova; Paras Karmacharya; Ali Duarte-Garcia; John M Davis; M Hassan Murad; Cynthia S Crowson
Journal:  Semin Arthritis Rheum       Date:  2020-04-09       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.